Yuanbin Cui

Title: **Yuanbin Cui: Innovator in Chimeric Antigen Receptor Development**

Introduction

Yuanbin Cui, an eminent inventor based in Guangdong, China, has made significant contributions to the field of biomedicine. With a focus on innovative therapies for treating tumors, Cui's work is marked by his development of a unique chimeric antigen receptor.

Latest Patents

Cui holds a patent for a scFv amino acid sequence, which is capable of recognizing the CD19 antigen. This patent, titled "ScFv amino acid sequence, chimeric antigen receptor containing same and application thereof," encompasses a nucleotide sequence encoding the scFv amino acid sequence, as well as its applications in manufacturing a medicament for treating tumors. The chimeric antigen receptor outlined in the patent incorporates at least one extracellular domain that binds to the CD19 antigen, along with an optional transmembrane domain and at least one intracellular costimulatory signaling domain. Notably, the humanized chimeric antigen receptor demonstrates a longer survival period in vivo, contributing to an extended complete remission period for patients.

Career Highlights

Cui is affiliated with Guangdong Zhaotai Invivo Biomedicine Co., Ltd., where he plays a crucial role in advancing innovative treatment options for cancer. His expertise and commitment to research have positioned him as a prominent figure within the biomedicine sector.

Collaborations

Throughout his career, Yuanbin Cui has collaborated with talented colleagues, including Peng Li and Ruocong Zhao. These partnerships showcase the importance of teamwork and collaboration in driving innovation and achieving breakthroughs in medical science.

Conclusion

Yuanbin Cui's inventive contributions to the field of biomedicine, particularly in developing chimeric antigen receptors, highlight his dedication to improving cancer treatment. His ongoing work promises to enhance therapeutic options for patients, making a lasting impact on the medical community.